Danish drugmaker Novo Nordisk is collaborating with Kallyope, a US biotech focused on the gut-brain axis, to discover novel peptide therapeutics for obesity and diabetes. Kallyope has developed a platform to interrogate the gut-brain axis, which plays a significant role in appetite regulation and energy homoeostatis, and discover new medicines in multiple therapeutic areas.

Under a joint research plan, the companies will work together on ‘in vitro’ and ‘in vivo’ studies to validate a number of product candidates. Following validation and option exercise, Novo will then take on responsibility for further preclinical and clinical development, manufacturing and commercialization. Novo has an option to license exclusive worldwide rights for up to six products.

“Coupling Novo Nordisk’s formidable capabilities with Kallyope’s unique, sophisticated platform makes for a very attractive strategic collaboration that complements our small molecule focus,” said Nancy Thornberry, Kallyope’s CEO.

Kallyope will receive an upfront payment and research support for activities under the collaboration, along with a license fee should Novo opt to take a therapy that has been discovered and validated under the partnership. The US biotech will also be eligible for potential research, development and sales milestones, along with sales royalties.